177 related articles for article (PubMed ID: 25856332)
1. Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation.
Wang X; Zhu D; Zhao C; He L; Du W
Metallomics; 2015 May; 7(5):837-46. PubMed ID: 25856332
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human prion neuropeptide PrP106-126 aggregation by hexacoordinated ruthenium complexes.
Wang X; Zhang B; Zhao C; Wang Y; He L; Cui M; Zhu X; Du W
J Inorg Biochem; 2013 Nov; 128():1-10. PubMed ID: 23911565
[TBL] [Abstract][Full Text] [Related]
3. Palladium complexes affect the aggregation of human prion protein PrP106-126.
Wang Y; Feng L; Zhang B; Wang X; Huang C; Li Y; Du W
Inorg Chem; 2011 May; 50(10):4340-8. PubMed ID: 21504185
[TBL] [Abstract][Full Text] [Related]
4. Regulation of aggregation behavior and neurotoxicity of prion neuropeptides by platinum complexes.
Wang X; Cui M; Zhao C; He L; Zhu D; Wang B; Du W
Inorg Chem; 2014 May; 53(10):5044-54. PubMed ID: 24787240
[TBL] [Abstract][Full Text] [Related]
5. Gold complexes inhibit the aggregation of prion neuropeptides.
Wang X; He L; Zhao C; Du W; Lin J
J Biol Inorg Chem; 2013 Oct; 18(7):767-78. PubMed ID: 23982344
[TBL] [Abstract][Full Text] [Related]
6. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
Webb MI; Walsby CJ
Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
[TBL] [Abstract][Full Text] [Related]
7. Roles of Apigenin and Nepetin in the Assembly Behavior and Cytotoxicity of Prion Neuropeptide PrP106-126.
Huo Y; Zhao C; Wang Y; Wang S; Mu T; Du W
ACS Chem Neurosci; 2024 Jan; 15(2):245-257. PubMed ID: 38133816
[TBL] [Abstract][Full Text] [Related]
8. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
9. Influence of gold-bipyridyl derivants on aggregation and disaggregation of the prion neuropeptide PrP106-126.
Zhao C; Wang X; He L; Zhu D; Wang B; Du W
Metallomics; 2014 Nov; 6(11):2117-25. PubMed ID: 25273168
[TBL] [Abstract][Full Text] [Related]
10. Comparison of KP1019 and NAMI-A in tumour-mimetic environments.
Gransbury GK; Kappen P; Glover CJ; Hughes JN; Levina A; Lay PA; Musgrave IF; Harris HH
Metallomics; 2016 Aug; 8(8):762-73. PubMed ID: 27460862
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of sesquiterpene lactones on the aggregation and cytotoxicity of prion neuropeptide.
Huo Y; Huang X; Wang Y; Zhao C; Zheng T; Du W
Biochimie; 2023 Aug; 211():131-140. PubMed ID: 36963557
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
13. The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
Alessio E; Messori L
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394024
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
[TBL] [Abstract][Full Text] [Related]
15. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
Nardon C; Brustolin L; Fregona D
Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
[TBL] [Abstract][Full Text] [Related]
16. Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.
Mu C; Chang SW; Prosser KE; Leung AW; Santacruz S; Jang T; Thompson JR; Yapp DT; Warren JJ; Bally MB; Beischlag TV; Walsby CJ
Inorg Chem; 2016 Jan; 55(1):177-90. PubMed ID: 26652771
[TBL] [Abstract][Full Text] [Related]
17. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
Groessl M; Zava O; Dyson PJ
Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
[TBL] [Abstract][Full Text] [Related]
18. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
Liu P; Jia J; Zhao Y; Wang KZ
Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
[TBL] [Abstract][Full Text] [Related]
20. Methionine oxidation of amyloid peptides by peroxovanadium complexes: inhibition of fibril formation through a distinct mechanism.
He L; Wang X; Zhu D; Zhao C; Du W
Metallomics; 2015 Dec; 7(12):1562-72. PubMed ID: 26444976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
